Polymyxin B

Therapeutic

Polymyxin B is indicated for the treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosa

Structural features

SMILES

[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O

Sequence

XXTXX(1)XfLXXT(1)

Molar mass

1203.499 g/mol

Constitutional members:

11

Natural amino acids

3

D-Amino acids

2

N-terminus

6-methyl-octanoyl

C-terminus

cycle

Cyclic

yes

Members/cycle

7

Bond to form cycle

head-to-side chain (Thr-Dab)

Lipidation

yes

Glycosylation

no

Route of administration

IM, IV, IT, OPHTALMIC, ORAL, TOPICAL

Terminal half-life

9-11.5 hours

Protein binding

92-99%

Absorption and Bioavailability

Administration by the oral route does not lead to absorption

References